Skip to main content

Table 2 Changes in laboratory variables among 2 arms

From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Variables

Empagliflozin

n = 43

Placebo

n = 39

Mean Diff

P

95% CI

Baseline

Week 26

Baseline

Week 26

Inflammatory

 IL-6 (pg/mL)

4.91 (1.83)

4.21 (1.13)

5.19 (2.10)

5.22 (1.84)

− 1.06

0.006

− 1.80; − 0.32

 IL-1b (pg/mL)

37.06 (10.36)

31.25 (9.58)

34.05 (10.24)

36.48 (10.50)

− 4.58

0.032

− 8.76; − 0.41

 Hs-CRP (mg/L)

10.07 (8.79)

6.14 (4.09)

9.85 (7.90)

9.03 (6.35)

− 2.86

0.003

− 4.71; -1.02

Oxidative stress

 SOD (U/mL)

12.58 (6.32)

16.91 (8.24)

11.22 (6.49)

12.18 (6.54)

3.70

0.002

1.36; 6.05

 CAT (mU/mL)

436.19 (148.58)

462.67 (157.70)

427.50 (101.81)

425.34 (128.23)

32.14

0.329

− 32.99; 97.26

 GSH (muM)

3.09 (0.74)

3.70 (0.90)

3.26 (0.95)

3.21 (0.81)

0.57

0.004

0.19; 0.95

 ROSa

1087.25 (687.91)

769.63 (598.84)

1010.22 (669.83)

1066.95 (679.95)

− 342.51

 < 0.001

− 474.23; − 210.79

 TAC (mmol/l)

645.38 (80.52)

917.17 (181.02)

666.49 (81.70)

793.51 (136.76)

124.08

0.002

47.98; 200.18

 MDA (nmol/mL)

6.25 (0.83)

6.09 (0.53)

6.31 (1.08)

6.24 (0.89)

− 0.13

0.350

− 0.41; 0.15

 PCGb (nmol/mg)

0.11 (0.5)

0.09 (0.06)

0.12 (0.06)

0.10 (0.05)

− 0.02

0.222

− 0.04; 0.01

Platelet function

 CD62-P Ag Expa

231.26 (37.96)

221.81 (38.51)

238.78 (32.93)

236.56 (34.97)

− 8.81

0.005

− 14.87; − 2.75

Glycemic status

 FBS (mg/dL)

163.14 (40.84)

145.23 (41.09)

167.74 (48.64)

169.08 (50.19)

− 18.60

 < 0.001

− 25.35; − 11.85

 HbA1c (%)

8.05 (0.97)

7.35 (1.04)

7.75 (0.94)

7.82 (0.91)

− 0.65

 < 0.001

− 0.83; − 0.48

 HOMA-IR

6.52 (3.17)

5.30 (2.89)

7.01 (3.48)

6.94 (3.53)

− 1.18

 < 0.001

− 1.47; − 0.89

  1. Data are presented as mean (SD)
  2. Abbreviations used are similar to Table 1
  3. aValues are presented as Mean fluorescent intensity (MFI).
  4. b Values are presented as the level of PCG/ mg of protein.